PYXS - Pyxis Oncology Inc

PYXS - Pyxis Oncology Inc

https://www.pyxisoncology.com

Recent News

Powered by Alpha Vantage

Should You Buy Pyxis Oncology, Inc. ( PYXS ) After Golden Cross?

Zacks Commentary • 2 hours, 1 minute ago • score: 0.40

Is it a good or bad thing when a stock experiences a golden cross technical event?

Pyxis Oncology to Participate in September Investor and Industry Conferences - Pyxis Oncology ( NASDAQ:PYXS )

Benzinga • 3 weeks, 4 days ago • score: 0.23

BOSTON, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Pyxis Oncology, Inc. PYXS, a clinical-stage company developing antibody-drug conjugate ( ADC ) therapeutics for difficult-to-treat cancers, today announced that Lara S.

Pyxis Oncology to Participate in September Investor and Industry Conferences

GlobeNewswire • 3 weeks, 4 days ago • score: 0.17

BOSTON, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Pyxis Oncology, Inc. ( Nasdaq: PYXS ) , a clinical-stage company developing antibody-drug conjugate ( ADC ) therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical ...

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Pyxis Oncology ( NASDAQ:PYXS )

Benzinga • 2 months, 2 weeks ago • score: 0.33

BOSTON, June 30, 2025 ( GLOBE NEWSWIRE ) -- Pyxis Oncology, Inc.

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )

GlobeNewswire • 2 months, 2 weeks ago • score: 0.36

BOSTON, June 30, 2025 ( GLOBE NEWSWIRE ) -- Pyxis Oncology, Inc. ( Nasdaq: PYXS ) , a clinical-stage company developing next-generation antibody-drug conjugate ( 'ADC' ) therapeutics for difficult-to-treat cancers, reported today that Pyxis Oncology's Compensation Committee of the Board of ...

Pyxis Oncology to Participate in Two Upcoming Investor Conferences - Pyxis Oncology ( NASDAQ:PYXS )

Benzinga • 4 months ago • score: 0.26

BOSTON, May 14, 2025 ( GLOBE NEWSWIRE ) -- Pyxis Oncology, Inc. PYXS, a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today announced that Lara S.

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

GlobeNewswire • 4 months ago • score: 0.20

BOSTON, May 14, 2025 ( GLOBE NEWSWIRE ) -- Pyxis Oncology, Inc. ( Nasdaq: PYXS ) , a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb) immunotherapies for treating cancers. The company is headquartered in Cambridge, Massachusetts.

52W High

$5.39

52W Low

$0.83

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.15

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

1.09

EV/Revenue (<3 favorable)

17.37

P/S (TTM) (<3 favorable)

42.01

P/B (<3 favorable)

1.35

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

23.39%

Institutions (25–75% balanced)

33.74%

Shares Outstanding

62,018,000

Float

41,180,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

2,820,000

Gross Profit (TTM)

2,820,000

EPS (TTM)

-1.59

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-6.76%

ROE (TTM) (>15% strong)

-0.75%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—